Ovarian Reserve in Crohn's Disease

Crohn Disease Clinical Trial

Official title:

Evaluation of Ovarian Reserve in Crohn's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03897400
• Other study ID #: 2019.03.40
• Status: Completed
• Start date: March 1, 2019
• Est. completion date: September 1, 2019

Study information

• Verified date: October 2019
• Source: Kanuni Sultan Suleyman Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Crohn's disease reduces fertility by inducing inflammation both directly and in the fallopian tubes and ovaries and indirectly through surgical interventions and tubal adhesions associated with disease treatment. Anti-mullerian hormone (AMH) is a reliable indicator of ovarian reserve in women. The aim of this study was to compare serum AMH levels in women with Crohn's disease and healthy controls. In this study, the investigators aimed to investigate AMH and ovarian capacity in the study group with crohn's disease and in the control group without disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: September 1, 2019
• Est. primary completion date: September 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• crohn's disease;

• reproductive age women

Exclusion Criteria:

• Over 40 years old,

• a previous ovarian resection;

• renal failure (serum creatinine levels N1.2 mg / dL);suspicion of malignancy;

• the presence of hereditary or acquired hematological disease;

• pregnancy;

• current lactation;

• the presence of a serious comorbid chronic disease;

• cirrhosis originating from chronic liver disease;

• abnormal thyroid function tests;

• a known serious psychological problem;

• presence of alcoholism and male sex.

Related Conditions & MeSH terms

• Anti-Mullerian Hormone Deficiency
• Crohn Disease
• Ovary Disease

Intervention

Other:
• AMH levels in young women with crohn's disease will be considered.
Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.

Locations

Country	Name	City	State
Turkey	Kanuni Sultan Süleyman Training and Research Hospital	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Kanuni Sultan Suleyman Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AMH levels	AMH levels of subjects taken into groups will be evaluated in lg/L	1 MONTH
Secondary	ultrasound findings	On the 3rd day of the menstrual cycle, the patients will be given ultrasound and the ovarian volume will be examined. the ovarian volume will be calculated by taking the size of the ovary in three sections.	1 MONTH